Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells
Open Access
- 21 October 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hepatology
- Vol. 53 (2), 548-557
- https://doi.org/10.1002/hep.24047
Abstract
Cholestasis leads to liver cell death, fibrosis, cirrhosis, and eventually liver failure. Despite limited benefits, ursodeoxycholic acid (UDCA) is the only Food and Drug Administration–approved treatment for cholestatic disorders. Retinoic acid (RA) is a ligand for nuclear receptors that modulate bile salt homeostasis. RA also possesses immunomodulatory effects and is used to treat acute promyelocytic leukemia and inflammatory disorders such as psoriasis, acne, and rheumatoid arthritis. To test whether the supplementation of RA with UDCA is superior to UDCA alone for treating cholestasis, male Sprague-Dawley rats underwent common bile duct ligation (BDL) for 14 days and were treated with phosphate-buffered saline (PBS), UDCA, all-trans retinoic acid (atRA), or UDCA and atRA by gavage. Treatment with UDCA and atRA substantially improved animal growth rates, significantly reduced liver fibrosis and bile duct proliferation, and nearly eliminated liver necrosis after BDL. Reductions in the bile salt pool size and liver hydroxyproline content were also seen with treatment with atRA or atRA and UDCA versus PBS and UDCA. Furthermore, atRA and UDCA significantly reduced liver messenger RNA and/or protein expression of transforming growth factor β1 (Tgf-β1), collagen 1a1 (Col1A1), matrix metalloproteinase 2 (Mmp2), cytokeratin 19, α-smooth muscle actin (α-SMA), cytochrome P450 7A1 (Cyp7a1), tumor necrosis factor α, and interleukin-β1. The molecular mechanisms of this treatment were also assessed in human hepatocytes, hepatic stellate cells, and LX-2 cells. atRA alone or in combination with UDCA greatly repressed CYP7A1 expression in human hepatocytes and significantly inhibited COL1A1, MMP2, and α-SMA expression and/or activity in primary human hepatic stellate cells and LX-2 cells. Furthermore, atRA reduced TGF-β1–induced Smad2 phosphorylation in LX-2 cells. Conclusion: Our findings indicate that the addition of RA to UDCA reduces the bile salt pool size and liver fibrosis and might be an effective supplemental therapy with UDCA for cholestatic diseases. (HEPATOLOGY 2011;53:548-557.)This publication has 34 references indexed in Scilit:
- Bile acids: regulation of synthesisJournal of Lipid Research, 2009
- Differential modulation of rat hepatic stellate phenotype by natural and synthetic retinoidsHepatology, 2004
- Smads 2 and 3 Are Differentially Activated by Transforming Growth Factor-β (TGF-β) in Quiescent and Activated Hepatic Stellate CellsOnline Journal of Public Health Informatics, 2003
- Ursodeoxycholic acid aggravates bile infarcts in bile duct–ligated and Mdr2 knockout mice via disruption of cholangiolesGastroenterology, 2002
- Regulation of Absorption and ABC1-Mediated Efflux of Cholesterol by RXR HeterodimersScience, 2000
- Quantitative Zymography: Detection of Picogram Quantities of GelatinasesAnalytical Biochemistry, 1994
- Regulation of extracellular matrix synthesis by transforming growth factor β1 in human fat-storing cellsGastroenterology, 1993
- Phenotypical modulation of liver fat-storing cells by retinoids: Influence on unstimulated and growth factor-induced cell proliferationJournal of Hepatology, 1992
- Isolated hepatic lipocytes and kupffer cells from normal human liver: Morphological and functional characteristics in primary cultureHepatology, 1992
- Retinoic acid modulates rat Ito cell proliferation, collagen, and transforming growth factor beta production.JCI Insight, 1990